Our CEO David Hallal joined CNBC's Fast Money yesterday to chat with Melissa Lee about the promise of Scholar Rock's leading anti-myostatin platform, our recently announced EMBRAZE data, and how Scholar Rock is working to #CreatePossibilities for children and adults living with SMA and additional rare, severe, and debilitating neuromuscular disorders. Watch the clip at the link here: https://lnkd.in/ePFRiP95 #ScholarRock #SMA
Scholar Rock
Biotechnology
Cambridge, Massachusetts 16,133 followers
Scholar Rock is a biopharmaceutical company that discovers, develops and delivers life-changing therapies
About us
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
- Website
-
https://scholarrock.com
External link for Scholar Rock
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2012
Locations
-
Primary
Get directions
301 Binney St
Cambridge, Massachusetts 02142, US
Employees at Scholar Rock
Updates
-
Today, we reported our Q2 business progress and financial results. Read the full press release here: https://lnkd.in/ea_WUv7x
-
-
We’re excited to officially introduce Matt Hubbard as our new Vice President & Head of Business Operations! Matt brings more than 25 years of experience in operations leadership, commercial development, and new product launches across the biopharma industry. He joined Scholar Rock last month and is playing a vital role in supporting a strong commercial build and preparing us for future growth. Welcome aboard, Matt!
-
-
What if #SMA stood for something beyond a diagnosis? At Scholar Rock, we believe SMA is just one part of the story—not the whole story. Through our #SeeMyAbilities campaign, we're spotlighting the people behind the diagnosis: individuals and caregivers who define themselves by more than a medical condition. Follow along as we amplify and celebrate the voices of the SMA community. #SMAAwareness #SpinalMuscularAtrophy #RareDisease
-
Scholar Rock has ambitions to serve the SMA community on a global scale. Delivering on that vision takes bold leadership—that's why we're thrilled to welcome Katie Hernandez, MBA as our new Head of Global Commercialization. With deep industry experience across seven new product launches, Katie brings the strategic insight and operational prowess needed to help us execute a successful U.S. launch and scale for long-term growth. Welcome aboard, Katie!
-
-
Over the past few weeks, we’ve welcomed the first wave of our growing field team—an exciting step forward as we prepare for our first potential commercial launch. From Neuromuscular Account Managers and Field Reimbursement Managers to Regional Clinical Specialists, Rx Onboarding Coordinators, and Medical Science Liaisons—each will play a critical role in shaping our readiness to deliver for the SMA community. We’re extremely grateful to have these talented individuals join us as we move toward this next chapter. Welcome to the Scholar Rock team! #CreatingPossibilities
-
-
It's time to focus on muscle. 🕐 In a survey by Cure SMA, 89% of adults with SMA report gaining muscle strength as their greatest unmet need. Learn how we're working to create possibilities that address this challenge: https://lnkd.in/eKB3gZtV
-
At Scholar Rock, we’re driven by our purpose—and inspired by the people at the heart of our mission. Their strength is why we show up every day, committed to advancing care for rare, severe, and debilitating neuromuscular disorders. Explore how our clinical programs are designed to meet the needs of the patients and families who fuel our efforts: https://lnkd.in/ewFiTEhP #ScholarRock #ClinicalTrials
-
-
The Scholar Rock team is still growing! Please join us in welcoming Bill Mroczka JD as our new VP of U.S. Value and Access. Bill brings a wealth of experience in rare disease access and reimbursement and has helped patients gain access to life-changing therapies at several leading biopharma companies. When we asked what drew him to Scholar Rock, Bill said: “I joined Scholar Rock because I believe in our mission and want our Market Access team to partner with US payers to help SMA patients access this important and potential first-in-class therapy as quickly as possible." We're excited to have him on board as we move closer to delivering on this mission. Welcome to the team, Bill! 👏
-
-
ICYMI: Scholar Rock CEO, David Hallal, joined CNBC's Fast Money to discuss our leading anti-myostatin platform, our Phase 2 EMBRAZE data, and how we are working toward #CreatingPossibilities for patients living with #SMA and other rare neuromuscular disorders. Watch his interview here: https://lnkd.in/ePFRiP95
-